Hara K, Izumikawa K, Suzuyama Y, Shigeno Y, Komori M, Tomita H, Sai M, Ikebe A, Iwasaki H, Saito A
Jpn J Antibiot. 1985 Mar;38(3):553-74.
A new macrolide antibiotic preparation, TMS-19-Q.O tablet, was used to investigate the efficacy in the treatment of patients with respiratory tract infection, and the results obtained were as follows: Three hundred and seven cases were included in this report, and overall efficacy rate was 76.2%. Especially high clinical effect (86.0%) was observed in the treatment of patients with pneumonia including mycoplasmal pneumonia. Bacteriological effect was 87.5% in 51 cases identified as single infection of Gram-positive cocci and was 48.0% in 34 cases Gram-negative rods infection. Side effects were observed in 11 cases (3.50%): gastrointestinal disorder in 8, eruption in 2 and other in 1. Abnormality in laboratory tests was observed in 23 cases, hepatic disorder in 13, renal disorder in 3 and other laboratory tests in 7. It was considered from the results of clinical and bacteriological efficacy in different dose study that dose of TMS-19-Q should be 600 mg.
一种新的大环内酯类抗生素制剂，TMS - 19 - Q.O片，用于研究其治疗呼吸道感染患者的疗效，结果如下：本报告纳入307例患者，总有效率为76.2%。在包括支原体肺炎在内的肺炎患者治疗中观察到特别高的临床疗效（86.0%）。在51例被鉴定为革兰氏阳性球菌单一感染的病例中，细菌学疗效为87.5%，在34例革兰氏阴性杆菌感染病例中为48.0%。11例（3.50%）出现副作用：8例胃肠道紊乱，2例皮疹，1例其他。23例出现实验室检查异常，13例肝功能紊乱，3例肾功能紊乱，7例其他实验室检查异常。从不同剂量研究的临床和细菌学疗效结果来看，TMS - 19 - Q的剂量应为600毫克。
